Physician profile
Andres Betts
NPI 1902965841
$4,021.27
in general payments reported to CMS, 2019-2025
39 companies · $256 in 2025
The $256 reported for 2025 was more than what 85% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $190 · 2021: $519 · 2022: $521 · 2023: $808 · 2024: $756 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,820.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $536.53 | 2019-2025 | Belbuca, Xtampza |
| Abbvie INC. | $494.14 | 2021-2024 | Qulipta, Ubrelvy |
| Medtronic, INC. | $464.22 | 2021-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $240.70 | 2019-2021 | |
| Stryker Corporation | $210.01 | 2019-2021 | |
| Saluda Medical Americas, INC. | $209.48 | 2025 | Evoke |
| Vertos Medical, INC. | $171.45 | 2019-2024 | Mild Device Kit |
| Amgen INC. | $166.35 | 2019-2022 | |
| Lilly USA, LLC | $150.28 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.58 | 2022 | |
| Scilex Pharmaceuticals INC. | $109.20 | 2019-2024 | Ztlido |
| Pfizer INC. | $95.79 | 2019-2024 | |
| Si-Bone, INC. | $85.81 | 2019-2024 | |
| Biotronik Nro, INC. | $83.51 | 2024-2025 | Prospera |
| Sentynl Therapeutics, INC. | $80.92 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $72.74 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $70.30 | 2022 | |
| Curonix LLC | $68.77 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Forte Bio-Pharma LLC | $45.35 | 2022 | |
| Redhill Biopharma INC. | $43.76 | 2021 | |
| Allergan, INC. | $40.02 | 2019 | |
| Valinor Pharma, LLC | $38.97 | 2023 | Movantik |
| Avanos Medical | $38.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.96 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $36.45 | 2020 | |
| Averitas Pharma INC. | $35.00 | 2024 | Qutenza |
| Almatica Pharma LLC | $27.72 | 2023 | Gralise |
| Tersera Therapeutics LLC | $27.51 | 2024 | Prialt |
| Indivior INC. | $25.16 | 2019 | |
| Nevro Corp. | $24.80 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $24.20 | 2020 | |
| Vertiflex, INC. | $20.67 | 2019 | |
| Spr Therapeutics, INC | $20.02 | 2024 | Sprint Pns System |
| Trevena, INC. | $17.30 | 2021 | |
| Baudax Bio INC. | $17.00 | 2021 | |
| Abbott Laboratories | $16.55 | 2023 | Eterna |
| Astrazeneca Pharmaceuticals LP | $13.33 | 2019 | |
| Shionogi INC | $12.93 | 2019 | |
| Depuy Synthes Sales INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Betts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.